FindTrial
Sign In

the change of IMT of carotide artery in RA with treatment of tocilizumab

the change of IMT of carotide artery in RA with treatment of tocilizumab - the change of IMT of carotide artery in RA with treatment of tocilizumab

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027241
Enrollment
50
Registered
2017-05-03
Start date
2015-08-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

tofacitinib

Sponsors

hiroshima clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Those with an active RA during the previous 12 weeks, despite prior treatment with methotrexate 12 mg per week

Exclusion criteria

Exclusion criteria: previous cardiovascular event, peripheral vascular disease, or diabetes mellitus

Design outcomes

Primary

MeasureTime frame
IMT—

Secondary

MeasureTime frame
plaque—

Countries

Japan

Contacts

Public Contactkensuke kume

hiroshima clinic rheumatology

kumekensuke@live.jp0822320707

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026